SCHEMBL2301221

SCHEMBL2301221

O=C1NCCN1c1ccc(S(=O)(=O)Nc2ccc(Br)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.50
MAPT P10636 5/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTR6 P50406 1/20 0.47
POLB P06746 1/20 0.47
ALDH1A1 P00352 4/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
ESR1 P03372 1/20 0.46
RECQL P46063 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
PKM P14618 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2300518 0.88 MAPT (0.61) MAPTCYP3A4CYP2C9HTTSMN1; SMN2
SCHEMBL2302229 0.87 HTR6 (0.47) MAPTSMN1; SMN2HTR6POLBALDH1A1
SCHEMBL14239653 0.87 MAPT (0.47) MAPTSMN1; SMN2HTR6POLBALDH1A1
SCHEMBL2301965 0.87 ALDH1A1 (0.60) MAPTALDH1A1MEN1KMT2ARECQL
SCHEMBL2305062 0.87 CES1 (0.58) MAPTHTTHTR6ALDH1A1MEN1
SCHEMBL2299887 0.86 HTR6 (0.56) MAPTHTR6ALDH1A1MEN1KMT2A
SCHEMBL2302718 0.85 HTR6 (0.50) SMN1; SMN2HTR6POLBMEN1KMT2A
SCHEMBL2303169 0.84 ALDH1A1 (0.58) MAPTNPSR1CYP1A2CYP3A4CYP2C19
SCHEMBL2357330 0.84 ALDH1A1 (0.61) MAPTNPSR1HTTHTR6ALDH1A1
SCHEMBL2301155 0.84 KMT2A (0.61) MAPTHTTSMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
US-9034888-B2 Substituted 2-imidazolidones and analogs UNIVERSITE LAVAL (CA) 2015-05-19 US disclosed
EP-2536693-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS Université Laval (CA) 2012-12-26 EP disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITE LAVAL (CA) 2012-12-06 US disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed
WO-2011100840-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS UNIVERSITé LAVAL (CA) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309777-A1 SUBSTITUTED 2-IMIDAZOLIDONES AND ANALOGS CCNY, RPS4Y1, TPX2 IDO1 1935/4885MAPT 4618/4885NPSR1 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.